Understanding the structural basis for inhibition of cyclin-dependent kinases. New pieces in the molecular puzzle

Current Drug Targets

Volumn 18, Issue 9, 2017, Pages 1104-1111

  Levin, Nayara M Bernhardt ^a   Pintro, Val Oliveira ^a   De Ávila, Maurício Boff ^a   De Mattos, Bruna Boldrini ^a   De Azevedo, Walter Filgueira ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Binding affinity; Cyclin dependent kinase; Drug design; Inhibitors; Machine learning; Neurodegenerative disease

Indexed keywords

ALANINE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; CYCLIN DEPENDENT KINASE 11; CYCLIN DEPENDENT KINASE 12; CYCLIN DEPENDENT KINASE 13; CYCLIN DEPENDENT KINASE 14; CYCLIN DEPENDENT KINASE 15; CYCLIN DEPENDENT KINASE 16; CYCLIN DEPENDENT KINASE 17; CYCLIN DEPENDENT KINASE 18; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 20; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 8; CYCLIN DEPENDENT KINASE 9; HALOGEN; LYSINE; UNCLASSIFIED DRUG; VALINE; PROTEIN KINASE INHIBITOR;

CHEMICAL BINDING; CRYSTALLOGRAPHY; DEGENERATIVE DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; HUMAN; HYDROGEN BOND; MACHINE LEARNING; MOLECULAR DOCKING; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; MOLECULAR MODEL;

CYCLIN-DEPENDENT KINASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS;

EID: 85022203134     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450118666161116130155     Document Type: Review

References (86)

1. Lim PS, Sutton CR, Rao S. Protein kinase C in the immune system: from signalling to chromatin regulation. Immunology 2015; 146(4): 508-22.
2. Huang JJ, Chu HX, Jiang ZY, et al. Recent advances in the structure-based and ligand-based design of IKKß inhibitors as anti-inflammation and anti-cancer agents. Curr Med Chem 2014; 21(34): 3893-917.
3. Passiglia F, Van Der Steen N, Raez L, et al. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? Curr Drug Targets 2014; 15(14):1284-92.
4. Jain P, Karthikeyan C, Moorthy NS, et al. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr Drug Targets 2014; 15(5): 539-50.
5. Son YK, Park H, Firth AL, Park WS. Side-effects of protein kinase inhibitors on ion channels. J Biosci 2013; 38(5): 937-49.
6. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79: 34-74.
7. Tang JF, Wen Q, Sun J, Zhang WM, Zhu HL. Advances in the researches on the biological activities and inhibitors of phosphatidylinositol 3-kinase. Anticancer Agents Med Chem 2014; 14(5): 673-87.
8. Takahara T, Maeda T. Evolutionarily conserved regulation of TOR signalling. J Biochem 2013; 154(1): 1-10.
9. Dello Russo C, Lisi L, Feinstein DL, Navarra P. mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia 2013; 61(3): 301-11.
10. Perrino BA. Regulation of gastrointestinal motility by Ca2+/calmodulin-stimulated protein kinase II. Arch Biochem Biophys 2011; 510(2): 174-81.
11. Malumbres M, Harlow E, Hunt T et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009; 11: 1275-6.
12. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
13. Murray AW. Cyclin-dependent kinases: regulators of the cell cycle and more. Chem Biol 1994; 1: 191-5.
14. Morgan DO. Principles of CDK Regulation. Nature 1995; 374: 131-4.
15. Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006; 12(9): 1056-64.
16. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007; 6(6): 464-79.
17. Meijer L, Pondaven P. Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. Exp Cell Res 1988; 174(1): 116-29.
18. Azevedo WF, Leclerc S, Meijer L, et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997; 243(1-2): 518-26.
19. Gray NS, Wodicka L, Thunnissen AM, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998; 281(5376):533-8.
20. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov 2016; 6(4): 353-67.
21. Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA Approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 2015; 21(21): 4760-6.
22. Lu J. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. J Hematol Oncol 2015; 8: 98.
23. Mangini NS, Wesolowski R, Ramaswamy B, et al. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. Ann Pharmacother 2015; 49(11): 1252-60.
24. Suh DH, Kim M, Kim HJ, Lee KH, Kim JW. Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol 2016; 27(6): e53.
25. Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel) 2016; 11(3): 167-73.
26. Chen Z, Wu Y, Liu Y, Yang S, Chen Y, Lai L. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hy-drolyase. J Med Chem 2011; 54(10): 3650-60.
27. Canduri F, Uchoa HB, de Azevedo WF Jr. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors. Biochem Biophys Res Commun 2004; 324(2): 661-6.
28. Perez PC, Caceres RA, Canduri F, de Azevedo WF Jr. Molecular modeling and dynamics simulation of human cyclin-dependent kinase 3 complexed with inhibitors. Comput Biol Med 2009; 39(2): 130-4.
29. Park H, Yeom MS, Lee S. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. Chembiochem 2004; 5(12): 1662-72.
30. Filgueira de Azevedo W Jr, Gaspar RT, Canduri F, et al. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. Biochem Biophys Res Commun 2002; 297(5): 1154-8.
31. de Azevedo WF Jr, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293(1): 566-71.
32. Krystof V, Cankar P, Frysová I, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006; 49(22): 6500-9.
33. Pisani P, Caporuscio F, Carlino L, Rastelli G. Molecular Dynamics Simulations and Classical Multidimensional Scaling Unveil New Metastable States in the Conformational Landscape of CDK2. PLoS One 2016; 11(4): 0154066.
34. Jeffrey PD, Russo AA, Polyak K, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995; 376(6538): 313-20.
35. Russo AA, Jeffrey PD, Patten AK, Massagué J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382: 325-31.
36. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000; 28(1): 235-42.
37. Berman HM, Battistuz T, Bhat TN, et al. The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 2002; 58(Pt 6 No 1): 899-907.
38. Westbrook J, Feng Z, Chen L, Yang H, Berman H M. The Protein Data Bank and structural genomics. Nucleic Acids Res 2003; 31(1): 489-91.
39. Vaughan CK, Gohlke U, Sobott F, et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 2006; 23(5): 697-707.
40. Tarricone C, Dhavan R, Peng J, Areces LB, Tsai LH, Musacchio A. Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell 2001; 8(3): 657-69.
41. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998; 395(6699): 237-43.
42. Lolli G, Lowe ED, Brown NR, Johnson LN. The crystal structure of human CDK7 and its protein recognition properties. Structure 2004; 12(11): 2067-79.
43. Schneider EV, Böttcher J, Blaesse M, Neumann L, Huber R, Maskos K. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. J Mol Biol 2011; 412(2): 251-66.
44. Baumli S, Lolli G, Lowe ED, et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J 2008; 9;27(13): 1907-18.
45. Brown NR, Korolchuk S, Martin MP, et al. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun 2015; 6: 6769.
46. Dixon-Clarke SE, Elkins JM, Cheng SW, Morin GB, Bullock AN. Structures of the CDK12/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding. Sci Rep 2015; 5: 17122.
47. Greifenberg AK, Hönig D, Pilarova K, et al. Structural and Functional Analysis of the Cdk13/Cyclin K Complex. Cell Rep 2016; 14(2): 320-31.
48. Malumbres M. Cyclin-dependent kinases. Genome Biology 2014, 15: 122.
49. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004; 32(5): 1792-7.
50. Benson ML, Smith RD, Khazanov NA, et al. Binding MOAD, a high-quality protein-ligand database. Nucleic Acids Res 2008; 36(Database issue): D674-8.
51. Ahmed A, Smith RD, Clark JJ, Dunbar Jr JB, Carlson HA. Recent improvements to Binding MOAD: a resource for protein–ligand binding affinities and structures. Nucleic Acids Res 2015; 43(Database issue): D465-9.
52. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a webaccessible database of experimentally determined protein– ligand binding affinities. Nucleic Acids Res 2007; 35(Database is-sue): D198–201.
53. Gilson MK, Liu T, Baitaluk M, Nicola G, Hwang L, Chong J. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 2016; 44(D1): D1045-53.
54. Wang R, Fang X, Lu Y, Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem 2004; 47(12): 2977-80.
55. Liu Z, Li Y, Han L, et al. PDB-wide collection of binding data: current status of the PDBbind database. Bioinformatics 2015; 31(3): 405-12.
56. Canduri F, de Azevedo WF. Protein crystallography in drug discovery. Curr Drug Targets 2008; 9(12): 1048-53.
57. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature 1993; 363(6430): 595-602.
58. Schulze-Gahmen U, De Bondt HL, Kim SH. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J Med Chem 1996; 39(23): 4540-6.
59. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93(7): 2735-40.
60. Kim SH, Schulze-Gahmen U, Brandsen J, de Azevedo Júnior WF. Structural basis for chemical inhibition of CDK2. Prog Cell Cycle Res 1996; 2: 137-45.
61. Lee J, Park T, Jeong S, Kim KH, Hong C. 3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett 2007; 17(5): 1284-7.
62. Mazanetz MP, Laughton CA, Fischer PM. Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer's disease. Molecules 2014; 19(7): 9134-59.
63. Mazanetz MP, Ichihara O, Law RJ, Whittaker M. Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method. J Cheminform 2011; 3(1): 2
64. Chen P, Lee NV, Hu W, et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther 2016; 15(10): 2273-81.
65. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006; 49(11): 3315-3321.
66. Otyepka M, Krystof V, Havlícek L, Siglerová V, Strnad M, Koca J. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem 2000; 43: 250625-13.
67. Tripathi SK, Soundarya RN, Singh P, Singh SK. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach. Chem Biol Drug Des 2015; 85(2): 107-18.
68. Ravitz O, Zsoldos Z, Simon A. Improving molecular docking through eHiTS' tunable scoring function. J Comput Aided Mol Des 2011; 25(11): 1033-51.
69. Azevedo LS, Moraes FP, Xavier MM. Recent Progress of Molecular Docking Simulations Applied to Development of Drugs. Curr Bioinform 2012; 7(4): 352-65.
70. De Azevedo WF Jr. MolDock applied to structure-based virtual screening. Curr Drug Targets 2010; 11(3): 327-34.
71. Ashtawy HM, Mahapatra NR. A Comparative Assessment of Predictive Accuracies of Conventional and Machine Learning Scoring Functions for Protein-Ligand Binding Affinity Prediction. IEEE/ ACM Trans Comput Biol Bioinform 2015; 12(2): 335-47.
72. Ashtawy HM, Mahapatra NR. Machine-learning scoring functions for identifying native poses of ligands docked to known and novel proteins. BMC Bioinformatics 2015; 16 Suppl 6:S3.
73. Khamis MA, Gomaa W, Ahmed WF. Machine learning in computational docking. Artif Intell Med 2015; 63(3): 135-52.
74. Li H, Leung KS, Wong MH, Ballester PJ. Improving AutoDock Vina Using Random Forest: The Growing Accuracy of Binding Affinity Prediction by the Effective Exploitation of Larger Data Sets. Mol Inform 2015; 34(2-3): 115-26.
75. Li H, Leung KS, Wong MH, Ballester PJ. Substituting random forest for multiple linear regression improves binding affinity prediction of scoring functions: Cyscore as a case study. BMC Bioinformatics 2014; 15: 291.
76. Ballester PJ, Schreyer A, Blundell TL. Does a more precise chemical description of protein-ligand complexes lead to more accurate prediction of binding affinity? J Chem Inf Model 2014; 54(3): 944-55.
77. Ashtawy HM, Mahapatra NR. A comparative assessment of ranking accuracies of conventional and machine-learning-based scoring functions for protein-ligand binding affinity prediction. IEEE/ACM Trans Comput Biol Bioinform 2012; 9(5): 1301-13.
78. Silva CG, Simoes CJV, Carreiras P, Brito RMM. Enhancing Scoring Performance of Docking-Based Virtual Screening Through Machine Learning. Curr Bioinform 2011; 11(4): 408-20.
79. Xavier MM, Heck GS, de Avila MB, et al. SAnDReS a Computational Tool for Statistical Analysis of Docking Results and Devel- opment of Scoring Functions. Comb Chem High Throughput Screen 2016; 19(10): 801-12.
80. Dias R, Timmers LF, Caceres RA, de Azevedo WF Jr. Evaluation of molecular docking using polynomial empirical scoring functions. Curr Drug Targets 2008; 9(12): 1062-70.
81. de Azevedo WF Jr, Dias R. Computational methods for calculation of ligand-binding affinity. Curr Drug Targets 2008; 9(12): 1031-9.
82. de Azevedo WF Jr, Dias R. Evaluation of ligand-binding affinity using polynomial empirical scoring functions. Bioorg Med Chem 2008; 16(20): 9378-82.
83. Wyatt PG, Woodhead AJ, Berdini V, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008; 51(16): 4986-99.
84. Samanta S, Debnath B, Basu A, Gayen S, Srikanth K, Jha T. Exploring QSAR on 3-aminopyrazoles as antitumor agents for their inhibitory activity of CDK2/cyclin A. Eur J Med Chem 2006; 41(10): 1190-5.
85. Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem 2009; 1(3): 187-92.
86. Aparoy P, Reddy KK, Reddanna P. Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors. Curr Med Chem 2012; 19(22): 3763-78.